Marvel Biosciences obtains financing to develop drug

Executive Summary

• Marvel Biosciences Corp. has secured funding and advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the research and development of a pediatric-friendly liquid formulation for its lead compound, MB-204.
• The project aims to create a small-volume oral liquid formulation designed specifically for children and adolescents with neurodevelopmental disorders, including autism spectrum disorder, Rett syndrome, and Fragile X syndrome, addressing challenges with swallowing pills or using feeding tubes.
• This initiative builds on MB-204's existing preclinical validation and is intended to generate data to support future clinical trials and regulatory engagement while keeping high-value pharmaceutical R&D activities in Canada.

Key Details

• Funding Source: National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
• Project Scope: Development of a small-volume oral liquid formulation of MB-204 suitable for pediatric use.
• Target Patient Population: Children and adolescents with neurodevelopmental disorders, specifically autism spectrum disorder, Rett syndrome, and Fragile X syndrome.
• Clinical Rationale: Many patients in these populations experience significant challenges swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer.
• Technical Goals: Evaluate multiple liquid formulation approaches to identify a stable and reproducible dosing format that can be administered in very small volumes (e.g., by oral syringe or feeding tube) without compromising drug exposure or consistency.
• Strategic Impact: The program aims to improve treatment accessibility, support patient adherence, and reduce the burden on families and caregivers. It also serves to expand Marvel's intellectual property portfolio and advance patient-centric therapies for neurological conditions.
• Operational Details: The project will be carried out with Canadian research partners and service providers.

Notable Quotes

• "Developing medicines that children can actually take is a very important, yet many times an overlooked part of drug development. This support will allow us to directly address a clinical barrier faced by patients and caregivers and prepare MB-204 dosing to be aligned with future pediatric clinical development." — Rod Matheson, Chief Executive Officer